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Abstract
Background: There is an ongoing debate over whether atypical antipsychotics are more effective than typical
antipsychotics in the treatment of schizophrenia. This naturalistic study compares atypical and typical
antipsychotics on time to all-cause medication discontinuation, a recognized index of medication effectiveness in
the treatment of schizophrenia.
Methods: We used data from a large, 3-year, observational, non-randomized, multisite study of schizophrenia,
conducted in the U.S. between 7/1997 and 9/2003. Patients who were initiated on oral atypical antipsychotics
(clozapine, olanzapine, risperidone, quetiapine, or ziprasidone) or oral typical antipsychotics (low, medium, or
high potency) were compared on time to all-cause medication discontinuation for 1 year following initiation.
Treatment group comparisons were based on treatment episodes using 3 statistical approaches (Kaplan-Meier
survival analysis, Cox Proportional Hazards regression model, and propensity score-adjusted bootstrap
resampling methods). To further assess the robustness of the findings, sensitivity analyses were performed,
including the use of (a) only 1 medication episode for each patient, the one with which the patient was treated
first, and (b) all medication episodes, including those simultaneously initiated on more than 1 antipsychotic.
Results: Mean time to all-cause medication discontinuation was longer on atypical (N = 1132, 256.3 days)
compared to typical antipsychotics (N = 534, 197.2 days; p < .01), and longer on atypicals compared to typicals
of high potency (N = 320, 187.5 days; p < .01), medium potency (N = 140, 213.5 days; p < .01), and low potency
(N = 74, 208.7 days; p < .01). Among the atypicals, only clozapine, olanzapine, and risperidone had significantly
longer time to all-cause medication discontinuation compared to typicals, regardless of potency level, and
compared to haloperidol with prophylactic anticholinergic treatment. When compared to perphenazine, a
medium-potency typical antipsychotic, only clozapine and olanzapine had a consistently and significantly longer
time to all-cause medication discontinuation. Results were confirmed by sensitivity analyses.
Conclusion: In the usual care of schizophrenia patients, time to medication discontinuation for any cause appears
significantly longer for atypical than typical antipsychotics regardless of the typical antipsychotic potency level.
Findings were primarily driven by clozapine and olanzapine, and to a lesser extent by risperidone. Furthermore,
only clozapine and olanzapine therapy showed consistently and significantly longer treatment duration compared
to perphenazine, a medium-potency typical antipsychotic.
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Background
Schizophrenia is often a severe and persistent mental ill-
ness, characterized by cognitive deficits, thought disor-
ganization, mood abnormalities, and multiple functional
deficits. Expert consensus guidelines for the treatment of
schizophrenia [1] have identified psychosocial interven-
tions and continuous antipsychotic medications as core
treatment modalities. Interruptions in antipsychotic ther-
apy have been shown to diminish treatment effectiveness
[2-4] and increase the risk of hospitalization [4-6], even
when the medication is interrupted for as little as 10 days
[3]. Despite consistent treatment recommendations and
recognition of the importance of continuous medication
treatment, only about 50% of schizophrenia patients are
adherent to antipsychotic medication regimens [7].
Consensus on the importance of continuous treatment
with antipsychotics has been accompanied, however, by
an ongoing debate over whether the newer "atypical"
antipsychotics are superior to the older "typical" antipsy-
chotics in the treatment of schizophrenia [8-13]. Some
have reported comparable efficacy [12] and questioned
the claims of superior efficacy of atypicals relative to typi-
cals [8,12,13] because clinical trials have often established
efficacy of the atypicals in comparison to haloperidol, a
high-potency typical antipsychotic known to have pro-
nounced treatment-emergent extrapyramidal symptoms
(EPS) that may contribute to poorer treatment outcomes.
Some researchers have claimed [8] that atypicals are of
comparable efficacy to typical antipsychotics of medium
or low potency, because lower-potency antipsychotics
have a more favorable EPS profile, and thus provide
greater tolerability and better outcomes. Others also
reported [12] that olanzapine is not more efficacious than
haloperidol when haloperidol is provided with prophy-
lactic anticholinergic treatment to help ameliorate EPS.
Time to all-cause medication discontinuation has been
recognized as an important global index of antipsychotic
effectiveness, because it reflects the judgment of both
patients and clinicians on the medication's effectiveness,
safety, and tolerability [14]. This global proxy measure of
medication effectiveness is the primary outcome measure
in the National Institute of Mental Health Clinical Antip-
sychotic Trials of Intervention Effectiveness (CATIE)
project [14], an important 18-month, randomized, dou-
ble-blind study comparing 1 typical antipsychotic (per-
phenazine) and 4 atypical antipsychotics (olanzapine,
risperidone, quetiapine, and ziprasidone) in the treat-
ment of schizophrenia in the United States. The CATIE
trial concluded that olanzapine was the most effective in
terms of discontinuation rates and time to discontinua-
tion [14]. The median time to discontinuation of treat-
ment for any cause was significantly longer in the
olanzapine group (9.2 months) than in the quetiapine
(4.6 months, p < .001) or risperidone group (4.8 months,
p = .002). The median time to all-cause treatment discon-
tinuation was also longer for olanzapine compared to per-
phenazine (5.6 months, p = .021) and ziprasidone (3.5
months, p = .028), but these differences lost their statisti-
cal significance following adjustments for multiple com-
parisons. It is important to note that for various reasons
[14], the specific comparisons involving perphenazine
and ziprasidone had a lower statistical power to identify
group differences in treatment discontinuation (statistical
power of 76% and 58% for perphenazine and ziprasi-
done, respectively, rather than 85%). It is unclear whether
findings from CATIE, a randomized, double blind study,
may generalize to open-label, naturalistic treatment in
usual care settings. The objective of this study is to com-
pare atypical and typical antipsychotics on time to all-
cause medication discontinuation in the usual care of
patients with schizophrenia spectrum disorders. We used
data from a large, prospective, non-randomized, non-
interventional, multisite, naturalistic study of schizophre-
nia patients in the United States. Using time to all-cause
medication discontinuation for 1 year following medica-
tion initiation, we first compared 5 atypical antipsychotics
(singly and combined) with typical antipsychotics of
high-, medium-, or low-potency level. Next, we compared
the atypicals (singly and combined) with 2 specific typical
antipsychotics: (a) perphenazine, a medium-potency typ-
ical antipsychotic, and (b) haloperidol with prophylactic
anticholinergic agents. Consistent with meta-analytical
findings from randomized clinical trials (RCTs) [9-11], we
hypothesized that during treatment of schizophrenia
patients in "real-world settings," time to medication dis-
continuation for any cause is longer for patients treated
with atypical than typical antipsychotics, regardless of
potency level, and that time to all-cause medication dis-
continuation will also differ among atypical antipsychot-
ics compared to typical agents.
Methods
Subjects and study design
We used data from the U.S. Schizophrenia Care and
Assessment Program (US-SCAP), a large (N = 2327), non-
randomized, multicenter, 3-year, prospective, naturalistic
study of patients treated for schizophrenia spectrum dis-
orders. The study was conducted between July 1997 and
September 2003, and its goal was to understand the treat-
ment of schizophrenia patients in usual care settings in
the United States [15-19]. Patients were recruited from
diverse geographical areas, including the Northeast,
Southwest, Mid-Atlantic, and West. The 6 participating
regional sites represented large systems of care, including
community mental health centers, university health care
systems, community and state hospitals, and the Depart-
ment of Veterans Affairs Health Services. Each participat-
ing site had to provide open and unrestricted access to allBMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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atypical antipsychotics available in the U.S. during the
study period (clozapine, risperidone, olanzapine,
quetiapine, and ziprasidone). Participants were adults -18
years and older with no upper age limit – treated for schiz-
ophrenia, schizoaffective, or schizophreniform disorders,
based on DSM-IV criteria, were geographically and ethni-
cally diverse, and represented treatment in large systems
of care. Patients were excluded if they were unable to pro-
vide informed consent or had participated in a clinical
drug trial within 30 days prior to enrollment. Institutional
Review Board (IRB) approval was received at each
regional site prior to initiation of the study, and informed
consent was received from all participants.
The study enrollment process used 2 recruitment strate-
gies simultaneously: random selection of outpatients
from site medical information rosters of active clients, and
sequential screening of inpatient admissions. Outpatients
were selected using de-identified lists of adults currently
receiving services at the site with diagnosis of schizophre-
nia spectrum disorders. Patient medication information
was excluded. Using a random number generator, outpa-
tients were selected at random. The de-identified lists were
refreshed every 6 months to replace the patients that had
been recruited, until each site reached the enrollment tar-
get (400 patients). Of 3332 patients who met the minimal
inclusion criteria noted above, 2327 (69.8%) enrolled,
765 (23.0%) refused, and 240 (7.2%) were not enrolled
due to other reasons. This screening information pertains
to inpatient and outpatients, as it was not collected sepa-
rately by inpatient/outpatient status. Almost all study par-
ticipants were outpatients at enrollment (2175/2327 or
93.5%). Of 2327 participants, most completed 1 year of
follow-up (78.1%), with fewer completing 2 years
(69.6%), and 3 years (65.2%). Enrollment was not con-
tingent upon being treated with a specific antipsychotic or
with any medication. Patients could continue with medi-
cations they received prior to enrollment for as long as
necessary, and decisions about medication changes, if
any, reflected those made by physicians and their patients,
as they naturally occur in usual practice.
Analytical sample
The analytical sample for the present study included treat-
ment episodes of patients who were initiated at any time
during the 3-year study or the 4 months prior to enroll-
ment on any oral antipsychotic and had at least 1 year of
follow-up in the study following initiation on the medica-
tion. Initiation was defined as the start of an antipsychotic
that was not prescribed during the previous 60 days or
more. Using an episode-of-care approach provides com-
prehensive information about the multiple courses of
treatment per participant in the longitudinal treatment of
the illness [20]. Figure 1 illustrates the treatment-episodes
approach, and the potential for overlap between treat-
ment episodes for any given patient during the 3-year
study. A total of 1666 treatment episodes of 1028 patients
met these criteria. The 1666 treatment episodes included
1132 on atypical antipsychotics and 534 on typical antip-
sychotics. The atypical treatment group was comprised of
clozapine (N = 114), olanzapine (N = 465), risperidone
(N = 350), quetiapine (N = 178), and ziprasidone (N =
25). The typical antipsychotic treatment group included
typicals of high potency (N = 320, haloperidol and flu-
phenazine); typicals of medium potency (N = 140, loxap-
ine, molindone, perphenazine, thiothixene, and
trifluoperazine); and typicals of low potency (N = 74,
chlorpromazine, mesoridazine, promethazine, and thior-
idazine). The medium-potency typical antipsychotic
group included perphenazine (N = 41), and the high-
Treatment-episodes approach Figure 1
Treatment-episodes approach. Abbreviations: RIS, risperidone; OLZ, olanzapine; HAL, haloperidol. Using the treatment 
episode approach, a patient may have initiated several treatment episodes over the course of this 3-year study. This figure 
shows an example of the treatment pattern of a patient with 3 treatment episodes. Patients were administered study measures 
at the end of each 6-month assessment period.
Enrollment 1 year 2 year 3 year
Assess 1 Assess 2 Assess 3 Assess 4 Assess 5 Assess 6 Assess7
RIS
HAL OLZBMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
Page 4 of 16
(page number not for citation purposes)
potency typical antipsychotic group included haloperidol
with prophylactic anticholinergics (N = 114). Prophylac-
tic use was defined as a prescription for an anticholinergic
medication written on the same date as, or 1 day later
than, the initiation date of haloperidol.
Measures
The primary outcome measure was time to all-cause med-
ication discontinuation. This measure assessed the
number of consecutive days from initiation of the index
antipsychotic to the start of the first medication gap larger
than 30 consecutive days during the first year following
initiation. Previous research has established the absence
of target medication for more than 14 days as a valid indi-
cator of drug discontinuation [4,21]. We opted to be more
conservative and used a larger gap to denote medication
discontinuation [22]. A medication gap could have
resulted from any number of events, including switching
to another antipsychotic or discontinuation of the antip-
sychotic drug. The manner in which we determined med-
ication gap size was based on periodic (every 6 months)
and systematic reviews of medical records using an
abstraction form developed for this study. Trained and
annually certified examiners used this form to collect
medication prescription information, which was used to
identify an absence of a prescription for each index antip-
sychotic for more than 30 consecutive days.
At enrollment and at 12-month intervals thereafter, par-
ticipants were assessed with various standard psychiatric
measures, but these planned study assessments were not
set to coincide with time of initiation or discontinuation
of any medication.
Statistical analysis
Treatment group comparisons on time to all-cause medi-
cation discontinuation were first made between the atyp-
icals as a group versus typicals as a group, then between
the atypicals (singly and combined) and typicals of high
potency, medium potency, and low potency levels. In
addition, the atypicals were compared (singly and com-
bined) with perphenazine, and then with haloperidol
with prophylactic anticholinergics.
Data analyses posed a number of analytical challenges
that were identified and addressed using the following
approaches:
a) Potential selection bias due to non-randomization
Treatment assignments in usual practice tend to reflect
patient's illness profile, prior medication use pattern, and
physician's medication preferences. To help address
potential selection bias of the treatment groups, we iden-
tified, a priori, a set of available covariates that were used
in the Cox Proportional Hazards regression model (cov-
ariates are listed later in this section). In addition, we used
propensity scores adjustment to balance the characteris-
tics of the treatment group comparisons [23].
b) Potential "period bias" due to differential time of medication 
introduction in the U.S
This issue was especially pertinent for antipsychotics that
were launched later (quetiapine and ziprasidone). To help
address potential "period bias," we included time to initi-
ation on the index antipsychotic from the starting date of
the US-SCAP study as a covariate in the Cox Proportional
Hazards regression model, and in the propensity score
method.
c) Skewed data distribution
The distribution of data on time to all-cause medication
discontinuation was found to be skewed. To address this
issue, bootstrapping method after propensity score adjust-
ment was used to compare the mean difference between
treatment groups on time to all-cause discontinuation
[24]. Other statistical methods (Kaplan-Meier survival
analysis and Cox Proportional Hazards regression mod-
els) that do not impose symmetry were used to confirm
the findings.
d) Potential bias due to episode approach
Use of treatment episode as the unit of analysis may create
bias, because 1 patient may have been initiated on several
medications over time, thus contributing multiple epi-
sodes. To address this issue, we performed a sensitivity
analysis, using each patient's first episode only.
e) Potential "sponsor-related physician bias"
Favorable perceptions of the pharmaceutical company
sponsoring the study may create preference of the spon-
sor's medication (olanzapine in this case) by participating
physicians over other antipsychotics. Although this poten-
tial bias cannot be ruled out by statistical methods, we
attempted to address physicians' potential preference to
switch patients to olanzapine soon after patients' enroll-
ment in the study. To that end, we performed an addi-
tional sensitivity analysis in which the time from patient's
enrollment in US-SCAP to the time of patient's initiation
on the index medication was used as a covariate in the
Cox Proportional Hazards regression model. We hypoth-
esized that if "sponsor-related physician bias" were
present, physicians would have quickly switched patients
from their current antipsychotic to olanzapine rather than
to risperidone (olanzapine, risperidone, and clozapine
were available for all patients at the time of enrollment,
unlike quetiapine and ziprasidone that were not yet avail-
able to early study enrollees).BMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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f) Lower statistical power due to smaller sample size of the 
ziprasidone treatment group
The smaller sample is likely due to various factors, includ-
ing later time to launch of ziprasidone in the U.S., and the
drugs' share of the total antipsychotic prescription market.
We were unable to statistically address the small sample
size problem and suggest, therefore, that the ziprasidone-
related findings be interpreted with caution.
To address these multiple analytical challenges, we used 3
separate statistical approaches for the main analysis and
performed 5 additional sensitivity analyses. For the main
analysis, all treatment group comparisons were made
using (a) Kaplan-Meier survival analysis (log-rank test),
(b) Cox Proportional Hazards regression model, and (c)
propensity score-adjusted bootstrap resampling method
with 1000 iterations. To address possible selection bias in
patients' assignment to medication groups in this non-
randomized study, we selected, a priori, a set of available
variables that were used to statistically adjust for possible
group differences at the time of initiation on the index
medication (in the Cox Proportional Hazards regression
model, and the propensity score method). Most of these
socio-demographic and treatment variables have been
previously reported to be related to nonadherence with
antipsychotic medication in the treatment of schizophre-
nia [25]. The covariates included age, gender, ethnicity,
comorbid diagnosis of substance use disorder, psychiatric
hospitalization in the 60 days prior to medication initia-
tion, time elapsed between medication initiation and
beginning of the US-SCAP study (01/07/1997), enroll-
ment site (1–6), schizoaffective disorder diagnosis (yes/
no), and duration on any antipsychotic in the 60 days
prior to initiation on the index antipsychotic.
The third main statistical approach used a propensity
score-adjusted bootstrap resampling method. To perform
this combined approach, we first calculated propensity
scores for each patient in each pairwise comparison using
a binary logistic model based on the covariates just pre-
sented. Next, the propensity scores were divided into bins
based on quintiles of the propensity score distribution.
We then used bootstrap resampling evenly across bins to
produce a sample from which we could compute a mean
treatment difference in days to all-cause medication dis-
continuation that was adjusted for the listed covariates.
This process was repeated 1000 times to create a distribu-
tion of days to all-cause discontinuation from which non-
parametric p-values for the mean treatment differences
were obtained.
In addition, 5 sensitivity analyses were performed (using
the Cox Proportional Hazards regression model with the
identified covariates) to address other potential sample
selection biases. In the first sensitivity analysis, only the
first episode for each patient was used (N = 1028). In the
second sensitivity analysis, all treatment episodes were
included (N = 1703, 1166 on atypicals, 537 on typicals),
thus adding treatment episodes on which patients were
simultaneously initiated on more than one antipsychotic
(adding 37 to the 1666 treatment episodes used in the
main analysis). The third sensitivity analysis assessed
"sponsor-related physician bias" by including the new
covariate just described: the time elapsed between medi-
cation initiation and the patient's enrollment date in the
study. This covariate replaced another covariate used in
the main analyses (time elapsed between medication ini-
tiation and beginning of US-SCAP). The fourth sensitivity
analysis assessed the robustness of the medication gap
Table 1: Patient characteristics at enrollment (n = 1028)
Characteristic Value
Age, years, mean (SD) 40.8 (11.0)
Male gender, % (n) 59.2 (609)
Ethnicity, % (n)
White 51.9 (553)
Black 39.2 (403)
Other 8.9 (92)
Schizoaffective disorder, % (n) 34.3 (353)
Illness duration, mean (SD) 20.7 (11.6)
Coverage by Medicaid and/or Medicare, % (n) 81.2 (835)
No health insurance % (n) 7.5 (77)
Substance use disorder, % (n) 28.8 (296)
Psychiatric hospitalization at enrollment or in prior 6 months, % (n) 25.6 (263)
Quality of Life Scale, total score, mean (SD) 73.9 (19.4)
MADRS, mean (SD) 15.7 (10.7)
PANSS, total score, mean (SD) 73.2 (18.6)
Abbreviations: SD, standard deviation; MADRS, Montgomery-Asberg Depression Rating Scale; PANSS, Positive and Negative Syndrome ScaleBMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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used to signal medication discontinuation (>30 days) by
repeating the analyses with the more customary "longer-
than-14-day" medication gap. The fifth and last sensitivity
analysis was an intent-to-treat (ITT) analysis, which unlike
previous analyses also included initiators on the index
drug who did not have data for at least 1 year following
initiation. The ITT approach was added to help address
the possibility that the study findings are limited to "1-
year study completers," and included 2488 treatment epi-
sodes (1722 on atypicals, 766 on typicals).
Although statistical tests were 2-tailed and significance
was set at .05 alpha level, we also pursued corrections for
multiple comparisons. This was done because we con-
ducted a large number of statistical comparisons, and a
few of them could have provided significant findings by
chance. Consistent with the CATIE trial [14], we used a
stepwise (gatekeeper) approach by means of a Hochberg
adjustment for multiple comparisons [26]. First, we tested
the differences between atypicals and typicals (Step 1).
When significance (p < .05) was found, we then tested
each atypical versus typicals as a class (5 comparisons, p =
.01 set as the threshold) (Step 2). Next, when significance
was found in Step 2 for a specific atypical, that atypical
was tested versus typicals of high, medium, and low
potency (3 comparisons, p = .017 set as the threshold)
(Step 3). Lastly (Step 4), once significant findings were
found in Step 3 for atypicals versus high-potency typicals,
we compared each atypical to haloperidol with prophy-
lactic anticholinergics; and once significant findings were
found in Step 3 for the atypicals versus medium-potency
typicals, we compared each atypical to perphenazine (5
comparisons, p = .017 set as the threshold).
Results
Patient characteristics
This study included 1666 treatment episodes of 1028
patients who were initiated on an oral antipsychotic and
had at least 1 year of follow-up in the study following
medication initiation. Of 1028 patients, 60% had 1 treat-
ment episode, 26% had 2 treatment episodes, 9% had 3
treatment episodes, and 5% had 4 or more treatment epi-
sodes.
At enrollment (Table 1), the 1028 patients were 40.8 years
old on average (age range 18–78) and were likely to be
male (59.2%) and White (51.9%). Most patients (81.2%)
had health care coverage by Medicaid or Medicare, or
both, and 7.5% were uninsured. Medicaid and Medicare
are public agencies that provide U.S. government and
state-funded health insurance coverage. Medicaid is a pro-
gram sponsored by the U.S. federal government and
administered by states to provide health-related services
to low-income individuals. Medicare is a U.S. federal
health insurance program for people age 65 and older and
for individuals with disabilities. On average, patients were
moderately and chronically ill with mild depressive symp-
toms, poor quality of life, and 20.7 years of illness dura-
tion. About a third were diagnosed with schizoaffective
disorder and 28.8% with comorbid substance use disor-
der. About one-fourth (25.6%) had a psychiatric hospital-
ization at enrollment or during the 6 months prior to
enrollment.
Available patient characteristics at baseline – the time of
initiation on the index drug – were fewer than characteris-
tics assessed at the time of patients' enrollment in the
study, because the assessments were not set to coincide
with time of initiation or discontinuation of any medica-
tion. Baseline characteristics for the treatment groups
prior to initiation are presented in Table 2. The treatment
Table 2: Patient characteristics at the time of medication initiation
Variable CLZ
N = 114
OLZ
N = 465
RIS
N = 350
QUE
N = 178
ZIP
N = 25
PER
N = 41
High
N = 320
Med
N = 140
Low
N = 74
HAL+AC
N = 114
Mean age, years 37.3 41.6 40.3 39.6 37.6 40.1 39.0 40.2 37.9 38.2
Male, % 57.0 60.2 54.6 47.2 24.0 56.1 58.8 60.0 64.9 57.0
African American, % 24.6 40.4 38.3 34.8 12.0 39.0 46.3 35.0 33.8 41.2
Substance use disorder, % 21.9 31.2 30.3 21.4 36.0 31.7 37.5 25.7 39.2 36.8
Psychiatric hospitalization in prior 2 
months, %
43.0 23.4 31.2 20.2 20.0 19.5 42.5 32.1 31.1 45.6
Mean time from study start to 
initiation, days
7000.3 656.0 689.7 828.4 1403.6 635.8 604.6 646.8 622.1 612.7
Schizoaffective disorder, % 34.2 32.0 34.3 39.9 60.0 29.3 32.2 37.1 33.8 32.5
Mean time on any antipsychotic in 
prior 2 months, days
51.6 49.1 46.4 55.7 57.8 38.3 44.8 42.7 49.2 46.8
Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, ziprasidone; PER, perphenazine; High, high-potency typical 
antipsychotics; Med, medium-potency typical antipsychotics; Low, low-potency typical antipsychotics; HAL+AC, haloperidol with prophylactic 
anticholinergic agents.BMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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groups differed in age, gender, ethnicity, comorbid diag-
nosis of substance use disorder, psychiatric hospitaliza-
tion in the 60 days prior to medication initiation, time
elapsed between medication initiation and beginning of
the US-SCAP study, schizoaffective disorder diagnosis,
and duration on any antipsychotic in the 60 days prior to
initiation on the index antipsychotic. As previously noted,
these variables were used as covariates in the analyses.
The mean (median) daily dose of each antipsychotic med-
ication group during the 1 year following its initiations, in
mg/day, was: 364.4 (356.6) for clozapine; 14.0 (12.3) for
olanzapine; 4.3 (4.0) for risperidone; 340.2 (297.3) for
quetiapine; and 107.6 (113.0) for ziprasidone. In addi-
tion, the average daily dose was 14.8 (8.0) for perphena-
zine, and 10.4 (9.3) for haloperidol with prophylactic
anticholinergic agents. The average daily doses were
within standard treatment range as noted in the drugs'
package inserts.
Atypicals versus typicals
During the 1 year following medication initiation, the
combined atypical antipsychotic group had significantly
longer treatment duration (256.3 days, SD = 137.2) than
the combined typical antipsychotic treatment group
(197.2 days, SD = 148.6; p < .01; Table 3, Figure 2). Simi-
larly, the combined atypical antipsychotic treatment
group had significantly (p < .01) longer treatment dura-
tion compared to typical antipsychotics of high, medium,
and low potency (Table 3). Survival curves are presented
in Figure 3 for atypicals as a group versus typicals of high-
, medium-, and low-potency levels.
When comparing each of the atypicals to the typicals
(combined), and to typicals of high-, medium-, or low-
potency level (separately), only clozapine, olanzapine,
and to a lesser extent risperidone were consistently associ-
ated with significantly longer time to medication discon-
tinuation (p < .05; Table 3). Treatment with clozapine and
olanzapine was associated with a significantly longer time
to discontinuation compared to treatment with high-,
medium-, or low-potency typical antipsychotics. Treat-
ment with risperidone was significantly longer than typi-
cals of high and medium potency but did not consistently
differ from typicals of low-potency level. Treatment with
quetiapine was significantly longer than with typicals of
high potency, did not consistently differ from typicals
(combined), and did not differ from typicals of medium-
or low-potency levels. Treatment with ziprasidone did not
significantly differ from typicals, regardless of potency
level. Findings maintained their significance following
correction for multiple comparisons (Steps 2 and 3). Fig-
ure 4 demonstrates that the likelihood of staying on an
atypical antipsychotic compared to typical antipsychotics
(combined) differed among the atypicals, such that only
clozapine, olanzapine, and risperidone had consistently
longer time to medication discontinuation compared to
treatment with typical agents. Table 5 presents the hazard
ratios (HR) and 95% confidence intervals of time to all-
cause medication discontinuation of each atypical agent
Table 3: Differences between atypical and typical antipsychotics of high, medium, and low potency on time to all-cause medication 
discontinuation
CLZ, OLZ, RIS, QUE, ZIP 
(combined)
CLZ OLZ RIS QUE ZIP
High-potency typicals
Log-rank test ** ** ** ** ** NS
Cox PH model ** ** ** ** * NS
Propensity score bootstrap ** ** ** ** * NS
Medium-potency typicals
Log-rank test ** ** ** * NS NS
Cox PH model ** ** ** * NS NS
Propensity score bootstrap ** ** ** * NS NS
Low-potency typicals
Log-rank test ** ** ** NS NS NS
Cox PH model * ** * * NS NS
Propensity score bootstrap ** ** ** * NS NS
All typicals
Log-rank test ** ** ** ** ** NS
Cox PH model ** ** ** ** NS NS
Propensity score bootstrap ** ** ** ** NS NS
Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, ziprasidone; NS, not significant *Significant at p < 0.05 level 
**Significant at p ≤ 0.01 levelBMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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versus all the typicals using the Cox Proportional Hazards
regression model. The HR varied greatly, ranging from
highest (for clozapine, HR = 3.51) to lowest (for ziprasi-
done, HR = 0.84).
Atypicals versus perphenazine
The combined atypical antipsychotic treatment group had
a significantly longer time to medication discontinuation
compared to treatment with perphenazine, using the 3
statistical methods (Table 4, Figure 2). These findings
were driven primarily by clozapine and olanzapine, as
treatment with risperidone did not differ from perphena-
zine on 2 of the 3 statistical methods, whereas treatment
with quetiapine or ziprasidone did not significantly differ
from perphenazine on any of the 3 statistical methods.
Figure 5 presents the probability of discontinuing the
medication during the 1 year following initiation for each
atypical antipsychotic compared to perphenazine, and
Table 5 presents the hazard ratios (HR) and 95% confi-
dence intervals of time to all-cause medication discontin-
uation of each atypical agent versus perphenazine using
the Cox Proportional Hazards regression model. The HR
varied greatly, ranging from highest (for clozapine, HR =
3.25) to lowest (for ziprasidone, HR = 0.76). Following
Mean time to all-cause medication discontinuation for atypical and typical antipsychotics Figure 2
Mean time to all-cause medication discontinuation for atypical and typical antipsychotics. Abbreviations: CLZ, 
clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, ziprasidone; PER, perphenazine; HAL+AC, haloperidol with 
prophylactic anticholinergic agents; High, high-potency typical antipsychotics; Med, medium-potency typical antipsychotics; 
Low, low-potency typical antipsychotics. Error bars represent standard deviations. Significant differences (p < .05) between 
high-potency typicals and CLZ, OLZ, RIS, QUE; between medium-potency typicals and CLZ, OLZ, RIS; between low-potency 
typicals and CLZ, OLZ, RIS; between perphenazine and CLZ, OLZ, RIS; and between haloperidol with prophylactic anticholin-
ergics and CLZ, OLZ, and RIS. Comparisons made with Cox Proportional Hazards regression model adjusted for patients and 
prior treatment characteristics.
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correction for multiple comparisons, clozapine and olan-
zapine maintained their initial significant differences. The
comparison between perphenazine and risperidone lost
its significance (p = 0.03, required p value = 0.017), while
comparisons with quetiapine and ziprasidone were
unchanged (non-significant).
Atypicals versus haloperidol with prophylactic 
anticholinergics
As presented in Table 6, the combined atypical antipsy-
chotic treatment group had a significantly longer time to
medication discontinuation compared to treatment with
haloperidol with prophylactic anticholinergic agents,
using the 3 statistical approaches.
These findings were driven primarily by clozapine, olan-
zapine, and risperidone, as quetiapine did not consist-
ently differ from haloperidol with prophylactic
anticholinergics, and treatment with ziprasidone did not
significantly differ from haloperidol with prophylactic
anticholinergics on any of the 3 statistical approaches.
Table 5 presents the hazard ratios and 95% confidence
intervals for time to medication discontinuation of each
atypical agent versus haloperidol with prophylactic anti-
cholinergic agents, using the Cox Proportional Hazards
regression model. The HR ranged from a highest for cloz-
apine (HR = 3.61) to the lowest for ziprasidone (HR =
0.71). Findings were unchanged following correction for
multiple comparisons (Step 4).
Survival rates: time to all-cause medication discontinuation for atypicals versus typicals of different potency levels Figure 3
Survival rates: time to all-cause medication discontinuation for atypicals versus typicals of different potency 
levels. Abbreviation: HAL+AC, haloperidol with prophylactic anticholinergics. Significant differences (p < .05) between the 
combined atypicals versus typicals of high, medium, and low potency, and versus haloperidol with prophylactic anticholinergics, 
using Cox Proportional Hazards regression model adjusted for patients and prior treatment characteristics.
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The average time to all-cause medication discontinuation
for each atypical antipsychotic, for perphenazine, and for
haloperidol with prophylactic anticholinergics are pre-
sented with standard deviation error bars in Figure 2.
Findings illustrate the ranking of the antipsychotics in the
following descending order: clozapine, olanzapine, risp-
eridone, quetiapine, perphenazine, ziprasidone, and
haloperidol with prophylactic anticholinergics.
The proportion of treatment episodes that were at least 1-
year long (conceptually similar to 1-year completer rates
in RCTs) was 73.7% for clozapine, 57.6% for olanzapine,
52.0% for risperidone, 46.1% for quetiapine, 28.0% for
ziprasidone, 30.9% for typicals of high-potency level,
43.6% for typicals of medium-potency level, 43.2% for
typicals of low-potency level, 36.6% for perphenazine,
and 30.7% for haloperidol with prophylactic anticholin-
ergics.
Sensitivity analyses
Results were essentially unchanged when the Cox Propor-
tional Hazards regression model was repeated (a) using 1
medication episode per patient (n = 1028), the one with
which the patient was treated first, (b) using 1703 treat-
ment episodes, including episodes where patients simul-
taneously initiated 2 or more treatment episodes, (c)
using the time elapsed between medication initiation and
patients' enrollment in the study, as a proxy for potential
"sponsor-related physician bias," (d) using a medication
gap >14 days to assess robustness of the >30-day medica-
tion gap used to signal medication discontinuation, and
(e) using ITT analysis, with 2488 treatment episodes, thus
Survival rates: time to all-cause medication discontinuation for clozapine, olanzapine, risperidone, quetiapine, ziprasidone ver- sus typicals Figure 4
Survival rates: time to all-cause medication discontinuation for clozapine, olanzapine, risperidone, quetiapine, 
ziprasidone versus typicals. Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, 
ziprasidone. Significant differences between CLZ, OLZ, and RIS versus the combined typicals at p < .05 using the Cox Propor-
tional Hazards regression model adjusted for patients and prior treatment characteristics.
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not requiring initiators to have continued in the study for
at least 1 year following medication initiation.
Only 1 of the 5 sensitivity analyses, the one using medica-
tion gap >14 days, provided different results on 2 specific
analyses. These analyses indicated that clozapine, olanza-
pine, risperidone, and quetiapine significantly (p < .05)
differ from the combined typical antipsychotic group, and
from haloperidol with prophylactic anticholinergics
(quetiapine did not significantly differ from these 2 treat-
ment groups in the main analyses).
Discussion
Consistent with findings from meta-analyses of rand-
omized, double-blind clinical trials [9-11], this large nat-
uralistic observational study found significant differences
between atypical and typical antipsychotics in the treat-
ment of schizophrenia. The present findings may help
extend and complement previous observations on treat-
ment duration in RCTs to treatment in usual clinical prac-
tice, using a clinically meaningful proxy measure of
medication acceptability that appears to capture the
patient and clinician judgments of the medication,
including symptomatic response, safety, and tolerability
[14]. Longer treatment duration was previously shown to
be associated with a lower risk of psychotic relapse and
psychiatric hospitalization [3-5,14,27], thus likely to
decrease patients' personal burden and lower the eco-
nomic costs for acute care in the mental health system [6].
Longer treatment duration was also found to be associ-
ated with greater symptom improvement [28] and better
functional outcomes in the treatment of patients with
schizophrenia [29].
More notably, this naturalistic study presents novel and
clinically important information about differences in
treatment duration between specific atypicals and specific
typicals (of high-, medium-, and low-potency levels; per-
phenazine, and haloperidol with prophylactic anticholin-
ergic agents). Findings demonstrate that compared to
typicals, the atypicals are not a homogeneous group in
usual clinical practice. Remarkably, not all the 5 studied
atypicals differentiated significantly and consistently from
typicals of various potency levels, as findings were prima-
rily driven by clozapine and olanzapine, and to a lesser
extent by risperidone. Furthermore, only clozapine and
olanzapine therapy showed consistently and significantly
longer treatment duration compared to perphenazine, a
medium-potency typical antipsychotic medication.
This study has also shown that some but not all atypical
antipsychotics are associated with significantly longer
treatment duration compared to haloperidol, when
haloperidol is provided with prophylactic anticholiner-
gics. Specifically, only clozapine, olanzapine, and risperi-
done were found to be associated with significantly longer
treatment duration compared to haloperidol with pro-
phylactic anticholinergic agents.
Current findings are consistent with several core findings
from the CATIE trial [14]. Despite substantial differences
in design and methodology between CATIE and US-SCAP
(e.g., CATIE is a randomized, double blind trial and US-
SCAP is non-randomized and non-interventional), both
studies found atypical antipsychotics to be a heterogene-
ous group on time to all-cause medication discontinua-
tion. When excluding clozapine, which was not included
in Phase 1 of CATIE, both studies found olanzapine-
treated patients to have the longest time to medication
discontinuation, followed in descending order by risperi-
done, quetiapine, and ziprasidone. In both studies, treat-
ment with olanzapine, but not with risperidone,
quetiapine, or ziprasidone, was associated with signifi-
cantly longer time to all-cause medication discontinua-
tion when compared with perphenazine. The statistically
significant difference versus perphenazine found in CATIE
(p = .021) lost, however, its significance following correc-
tions for multiple comparisons (required p value ≤ .017).
Table 4: Differences between atypical antipsychotics and perphenazine on time to all-cause medication discontinuation
Antipsychotic Statistical approach
Survival analysis, log-rank test Cox PH model Propensity score bootstrap
CLZ, OLZ, RIS, QUE, ZIP 
(combined) vs. PER
** * *
Clozapine vs. PER ** ** **
Olanzapine vs. PER ** ** **
Risperidone vs. PER NS * NS
Quetiapine vs. PER NS NS NS
Ziprasidone vs. PER NS NS NS
Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, ziprasidone; NS, not significant; PER, perphenazine.
*Significant at p < 0.05 level
**Significant at p ≤ 0.01 levelBMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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However, when similar stepwise corrections for multiple
comparisons were performed in the US-SCAP analyses,
the findings were essentially unchanged, still favoring
olanzapine over perphenazine. Current findings suggest
that if time to all-cause medication discontinuation in
usual care were to reflect medication effectiveness as it
does in CATIE [14], than the effectiveness of clozapine
and olanzapine relative to perphenazine, and the effec-
tiveness of clozapine, olanzapine, and risperidone relative
to haloperidol, may not be overestimated in usual care
settings.
Our findings of differential treatment duration in usual
care between typicals and atypicals are also consistent
with previous reports of a lower rate of treatment failure
and longer time to drug discontinuation [11,30-33]
among schizophrenia patients treated with atypicals com-
pared with typicals. Generally, there appears to be a 2-fold
increased risk of drug discontinuation with typicals com-
pared with atypicals [34]. Current findings are, however,
inconsistent with a meta-analysis by Wahlbeck and col-
leagues [35], who reported lack of significant differences
in dropout rates between typicals and atypicals other than
clozapine. That meta-analysis included 163 randomized
clinical trials, most of which were short-term, placebo-
controlled trials. Importantly, the authors did not per-
form direct head-to-head comparisons of typicals and
atypicals. When direct comparisons between typicals and
atypicals were performed in another meta-analysis [36],
the findings supported the superiority of atypicals over
typicals on "treatment failure" that captured dropout rates
and symptomatic relapse.
Consistent with prior research in usual care setting [37],
we also found clozapine to be associated with the longest
time to medication discontinuation, a finding that is con-
gruent with clozapine's greater efficacy in meta-analytical
reviews [8,9,11,35]. It is unclear, however, whether cer-
tain confounds are responsible for this finding. Unlike
treatment with other antipsychotics, treatment with cloz-
apine requires periodic blood monitoring to assess the
risk of developing agranulocytosis. In addition to the
likely initial selection of more adherent patients for treat-
ment with clozapine in usual care, the frequent monitor-
Table 5: Hazard ratios of time to medication discontinuation for 
atypical antipsychotics versus all typicals, versus perphenazine 
and versus haloperidol with prophylactic anticholinergics
Treatment groups Hazard ratios (95% 
confidence interval)
Clozapine vs. All Typicals 3.51** (2.39, 5.18)
Olanzapine vs. All Typicals 1.74** (1.45, 2.08)
Risperidone vs. All Typicals 1.56** (1.29, 1.88)
Quetiapine vs. All Typicals 1.24** (0.97, 1.58)
Ziprasidone vs. All Typicals 0.84 (0.49, 1.44)
Clozapine vs. Perphenazine 3.25** (1.70, 6.21)
Olanzapine vs. Perphenazine 1.76** (1.15, 2.70)
Risperidone vs. Perphenazine 1.60* (1.04, 2.46)
Quetiapine vs. Perphenazine 1.06 (0.64, 1.77)
Ziprasidone vs. Perphenazine 0.76 (0.25, 2.33)
Clozapine vs. Haloperidol + 3.61** (2.26, 5.78)
Olanzapine vs. Haloperidol + 1.89** (1.43, 2.51)
Risperidone vs. Haloperidol + 1.71** (1.29, 2.25)
Quetiapine vs. Haloperidol + 1.33 (0.94, 1.88)
Ziprasidone vs. Haloperidol + 0.71 (0.32, 1.58)
Abbreviations: Haloperidol + denotes the use of haloperidol with 
prophylactic anticholinergic agent.
Prophylactic use of anticholinergics is defined as a prescription for 
haloperidol and an anticholinergic on the date haloperidol was 
initiated, or 1 day later.
*Significant at p < 0.05 level
**Significant at p ≤ 0.01 level
Table 6: Differences between atypicals and haloperidol with prophylactic anticholinergic agents on time to all-cause medication 
discontinuation
Antipsychotic Statistical approach
Survival analysis, log-rank test Cox PH model Propensity score bootstrap
CLZ, OLZ, RIS, QUE, ZIP 
(combined) vs. HAL+
** ** **
Clozapine vs. HAL+ ** ** **
Olanzapine vs. HAL+ ** ** **
Risperidone vs. HAL+ ** ** **
Quetiapine vs. HAL+ ** NS NS
Ziprasidone vs. HAL+ NS NS NS
Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, ziprasidone; NS, not significant; HAL+ denotes the use of 
haloperidol with prophylactic anticholinergic agent.
*Significant at p < 0.05 level
**Significant at p ≤ 0.01 level
Prophylactic use of anticholinergics is defined as a prescription for haloperidol and an anticholinergic on the date haloperidol was initiated, or 1 day 
later.BMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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ing may help increase treatment duration with clozapine.
Support for this hypothesis comes from randomized dou-
ble-blind trials of clozapine versus olanzapine [38,39], in
which the treatment groups did not significantly differ on
dropout rates, possibly because the double-blind design
required both treatment groups to undergo regular moni-
toring with blood tests.
There is growing interest in naturalistic studies that com-
pare, among other variables, the differences in treatment
duration between specific atypical and typical antipsy-
chotics. Two very large, naturalistic, prospective, 3-year
studies have been recently completed, reporting findings
consistent with US-SCAP. One is the European Schizo-
phrenia Outpatient Health Outcomes (EU-SOHO, N =
10,972), which was conducted in 10 European countries
[30], and the other is the Inter-Continental SOHO (IC-
SOHO, N = 7658), conducted in 27 other countries
[31,32]. In addition, a recent naturalistic study of 2230
first-episode schizophrenia patients hospitalized in Fin-
land [40] compared monotherapy treatment with various
typical and atypical antipsychotics. The authors found the
first- and second-generation antipsychotics to be highly
heterogeneous groups with regard to effectiveness in a
real-world setting, and reported that patients treated with
clozapine or olanzapine had substantially lower discon-
tinuation rates of their initial treatment than patients
treated with haloperidol. In another recent study [41], our
group conducted a post hoc analysis of time to all-cause
medication discontinuation using data from a 1-year, ran-
domized, open-label study of schizophrenia patients
treated with olanzapine, risperidone, or typical antipsy-
chotics. Findings from that post hoc analysis were almost
identical to the present study. Namely, the 1-year survival
rate for patients randomized to olanzapine was signifi-
cantly higher than it was for patients randomized to typi-
cal antipsychotics of high-, medium-, or low-potency
levels, and compared to perphenazine. The survival rate
for patients randomized to risperidone was significantly
higher than typicals of high- or medium-potency levels
but did not significantly differ from olanzapine, from typ-
icals of low potency, or from perphenazine.
Current findings need to be interpreted in light of their
limitations. First, the non-randomized, naturalistic design
of this study introduced potential selection bias, which
cannot be completely eliminated despite our use of statis-
tical adjustments for a set of socio-demographic and treat-
ment characteristics. The treatment groups may have
differed on unobserved (thus unadjusted), pre-existing
measures, such as symptom severity at the time of medi-
cation initiation. As noted earlier, US-SCAP did not assess
patients' symptomatology at the time of medication initi-
ation, only at predetermined intervals. Other confounds
may have also affected the findings. These include the
potential period bias, episode bias, and the potential for
preference of the sponsor's medication (olanzapine) over
other atypicals by participating physicians. One cannot
completely adjust for these biases using statistical models,
especially not the potential "sponsor bias." It should be
noted, however, that the treating clinicians in the US-
SCAP study were not connected to the study and were gen-
erally unaware that particular patients were participating
in the study. Furthermore, if treating clinicians were
biased in favor of the sponsor and its drug, one would
have expected clinicians to quickly switch patients to
olanzapine from antipsychotics they were receiving at
enrollment. This phenomenon was not found when
assessed with a sensitivity analysis. It is also important to
note that the 3 statistical approaches used in this study
and the 5 additional sensitivity analyses did provide con-
sistent findings. Furthermore, our core findings on differ-
ential effectiveness between typicals and atypicals are
highly consistent with those found in prior RCTs [9-
11,15,42], in retrospective claims database studies
[4,21,43,44], and in naturalistic prospective studies [4,30-
33,40].
A second study limitation is the small sample size of the
ziprasidone treatment group, which limited the statistical
power of the analyses. It should be noted, however, that
the current findings are consistent with CATIE [14], in
which the ziprasidone-treated patients had the shortest
median time to all-cause discontinuation (3.5 months in
the 18-month trial) among the 5 treatment comparators,
and the highest rate of discontinuation rate for any cause
(79%). These findings were not statistically significant,
likely due to much-reduced statistical power (change from
85% power for comparisons versus other atypicals to 58%
power versus ziprasidone).
Third, our study was not designed to assess reasons for ini-
tiation or discontinuation of the antipsychotic medica-
tions. Findings from recent research suggest, however, that
in addition to patient preferences, antipsychotic medica-
tion efficacy [14,28], rather than safety or poor tolerabil-
ity, is the primary reason for medication discontinuation
in the treatment of schizophrenia.
And lastly, this study did not require patients (or treat-
ment episodes) to be confined to antipsychotic mono-
therapy. Although our approach did not distinguish
between the augmenting and augmented antipsychotics,
it is important to note that augmentation roles change
over time due to prevalent switching of antipsychotics, a
phenomenon we captured in analyses with multiple treat-
ment episodes. Furthermore, antipsychotic switching
processes are often characterized by medication overlap
with cross-titration, which amounts to short-term (and at
times prolonged) antipsychotic polypharmacy, thus mak-BMC Psychiatry 2006, 6:8 http://www.biomedcentral.com/1471-244X/6/8
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ing true monotherapy treatment episodes relatively rare
and possibly not representative of the complex treatment
regimens in real-world practice. Most importantly, the
current findings are highly consistent with RCTs [14,42]
and 3 large naturalistic studies conducted outside of the
U.S. that included only monotherapy-treated patients
[30-32,40].
The strengths of this study lie primarily in its prospective,
naturalistic, real-world, long-term perspective; its large
sample size; the use of an observational approach without
any planned treatment intervention; the ability to provide
comparative data on a number of commonly used antip-
sychotics; the ability to generalize the findings to patients
treated in large public systems of care across the United
States; and the availability of medication information
during hospitalizations, a type of data that is typically
absent in claims databases. Further, this study offers com-
prehensive medication information because patients were
also queried about use of psychiatric medications outside
of their regular treatment site. When this occurred, sys-
tematic efforts were made to abstract this out-of-site infor-
mation. Additional strengths of this study lie in its use of
multiple statistical approaches and sensitivity analyses, to
help check the robustness of the findings, and the ability
to proactively address several analytical challenges that
are inherent in analyses of naturalistic, longitudinal data.
Conclusion
This study found that in the usual care of patients with
schizophrenia spectrum disorders, there are significant
differences in time to medication discontinuation for any
Survival rates: time to all-cause medication discontinuation for clozapine, olanzapine, risperidone, quetiapine, ziprasidone ver- sus perphenazine Figure 5
Survival rates: time to all-cause medication discontinuation for clozapine, olanzapine, risperidone, quetiapine, 
ziprasidone versus perphenazine. Abbreviations: CLZ, clozapine; OLZ, olanzapine; RIS, risperidone; QUE, quetiapine; ZIP, 
ziprasidone; PER, perphenazine. Significant treatment group differences between CLZ, OLZ, and RIS versus perphenazine at p 
< .05, using Cox Proportional Hazards regression model adjusted for patients and prior treatment characteristics.
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cause between typical and atypical antipsychotics, regard-
less of the typical antipsychotic potency level, or when the
typical antipsychotic is augmented with prophylactic anti-
cholinergic treatment to ameliorate EPS. Findings suggest
that naturalistic studies may complement RCTs and facil-
itate interpreting their meaning for usual practice in real-
world settings. In addition, findings have shown that
atypical antipsychotics are not a homogeneous group,
because not all the studied atypicals differentiated signifi-
cantly and consistently from typicals of various type or
potency levels. And lastly, this study demonstrated the
utility of a simple and global index- time to all-cause med-
ication discontinuation – to help clinicians, patients, and
policymakers measure discernable and important differ-
ences between treatment options in the usual care of
patients with schizophrenia.
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